近5年承担课题：

1.  82072328,慢生长分枝杆菌LprA氨基端序列多态性对蛋白功能的影响及其诊断价值研究, 国家自然科学基金(面上项目), 2021-2024, 55万元

2.   首发2020-2-2161，高剂量异烟肼对已发生异烟肼耐药的结核病患者早期杀菌活性研究，首都卫生发展科研专项（自助创新），2020-2022，30万元

3.        #665357,RePORTInternational Supplemental Funding RFP，Dynamic detection ofcytokines by liquid chip technology to evaluate the efficacy ofanti-tuberculosis treatment.美国NIH，2019-2021, 35万美元

4.   YH201905，北京市通州区“运河”人才计划，2019-2023,25万元

5.   2018ZX10302301-004，菌阴结核病与非结核分枝杆菌病鉴别诊断的创新技术研发与应用研究，科技部国家科技重大专项，十三五传染病重大专项子课题，320.71万元

6.   Z181100001718092，首都临床特色应用研究，联合药物基因组学和群体药代动力学探讨结核性脑膜炎患者异烟肼合理的用药剂量和给药间隔，2018.06-2020.06，16万元

7.   ZYLX201809，北京市医院管理局“扬帆计划”：重点医学专业发展计划，2018-2020，100万元

8.   DFL20181602,北京市医院管理局“登峰”人才培养计划,2018-2021，94.34万元”

9.   2017ZX10201301-004-002，菌阴结核病和结核分枝杆菌潜伏感染相关生物标志物研究.科技部国家科技重大专项，十三五传染病重大专项子任务，179.47万元

10.  81672065， 结核分枝杆菌和牛分枝杆菌对噻吩二羧酸肼敏感/耐受的机制研究 国家自然科学基金(面上项目), 2017-2020, 52万元

近5年发表文章：

1. Wang G§,Huang M§, Jin H§,Jia J,Dong L,Wang F,Xue Y,Deng Y*, Jiang G*, Huang H*. The practical value of XpertMTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a high tuberculosisburden setting: a prospective multicenter diagnostic accuracy study.Microbiology Spectrum,2022,;e0094922

2. Yu X§,Zhang T§,Kong Y§,Wang F,Dong L,Han M*,Huang H* Xpert MTB/RIFUltra outperformed the Xpert assay in tuberculosis lymphadenitis diagnosis: aprospective head-to-head cohort study. International Journal of InfectiousDiseases,2022,122:741-6

3. Rui Zhu§, Xia Yu§, Tingting Zhang, Yaoyao Kong, Fen Wang,Junnan Jia, Yi Xue, and Hairong Huang*. In Vitro andIntracellular Inhibitory Activities of Nosiheptide Against MycobacteriumAbscessus. Front Microbiol. 2022

4. Chen S§, Wang F§, Xue Y, Huo F, Jia J, Dong L,Zhao L, Jiang G*, Huang H*. Doubled Nontuberculous Mycobacteria Isolation as aConsequence of Changes in the Diagnosis Algorithm. Infect Drug Resist. 2022,15:3347-3355

5.   Wang G§, Liang R§,Sun Q, Liao X, Wang C, Huang H*.Extremely high levels of central nervoussystem involvement in miliary tuberculosis. BMC InfectiousDiseases，2022, 22(1):417

6. Tingting Zhang§, Xia Yu§, Shu'an Wen, Yi Xue, Hua Xiao, Ruyan Ren, Fen Wang, LinglingDong, Shibing Qin*, Hairong Huang*. Bone penetration of cycloserine in osteoarticular tuberculosispatients of China. Antimicrob Agents Chemother.

7. Wei-wei Jiao§, Gui-rong Wang§, Lin Sun, Jing Xiao, Jie-qiong Li, Yacui Wang, Shu-Ting Quan, Hai-rong Huang*,A-dong Shen*. Multiple cross displacement amplification combined withReal-time PCR platform: a rapid, sensitive method to detect Mycobacteriumtuberculosis. Frontiers in Microbiology,2022 

8. DuJ, Li Q, Liu M, Wang Y, Xue Z, Huo F, Zhang X, Shang Y, Li S, Huang H, Pang Y.Distinguishing Relapse From Reinfection With Whole-Genome Sequencing inRecurrent Pulmonary Tuberculosis: A Retrospective Cohort Study in Beijing,China.Front Microbiol. 2021, 12:754352. doi: 10.3389/fmicb.2021.754352.eCollection 2021.PMID: 34956119 

9. YuX,Huo F,Wang F,Wen S,Jiang G,Xue Y,Dong L,Zhao L,Zhu R, Hairong Huang*. In Vitro antimicrobial activity comparison oflinezolid, tedizolid, sutezolid and delpazolid against slowly growingMycobacteria isolated in Beijing, China. Infection and Drug Resistance,2021 

10. ZhumanZhang§, Jian Du§,Tao Liu§, Feng Wang, JunnanJia, Lingling Dong, Liping Zhao,Yi Xue, Guanglu Jiang, Xia Yu*, Hairong Huang*.EasyNAT MTC Assay: ASimple, Rapid, and Low Cost Cross-Priming Amplification Method for Detection ofMycobacterium Tuberculosis Suitable for Point-of-Care Testing. Emerging Microbes & Infections.doi：10.1080/22221751.2021.1959271

11. Wen S§,Gao X§,Zhao W§, Huo F, Jiang G,DongL, Zhao L,Wang F,Yu X*,Huang H*. Comparison of the invitro activity of linezolid, tedizolid, sutezolid, and delpazolid againstrapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis.2021;109:253-260. doi: 10.1016/j.ijid.2021.06.055. 

12. JunFan§, Tinglong Lan§, Kai Tang§, Guirong Wang§,Weijie Dong, Dawei Li, Guangxuan Yan,Yuan Li, Guohua Lei, Jianlin Shan, QingleiWang, Jianhua Ma, Hairong Huang*, ShibingQin*.The comparative influence of 2 and 4 week preoperative anti-tuberculosistreatment on spinal tuberculosis surgery: a multicenter, prospective randomizedclinical trial. Infectious Diseases and Therapy.2021. doi:10.1007/s40121-021-00462-2. 

13. GuanLiu§, Xia Yu§，JingjingLuo,Yanjie Hu,Lingling Dong, Guanglu Jiang, FengminHuo,Fen Wang,Qian Liang, HairongHuang* .Mycobacteriumvicinigordonae sp.nov.,a slow growing scotochromogenic species isolatedfrom sputum. International Journal of Systematic and EvolutionaryMicrobiology.2021,71(5). doi: 10.1099/ijsem.0.004796 

14. Shan Gao§, Chong Wang§, Xia Yu§, Tianlu Teng, Yuanyuan Shang, Junnan Jia, LinglingDong,Liping Zhao, Shuku Liu*, Naihui Chu*, Hairong Huang*.Xpert MTB/RIF Ultra enhancestuberculous pleurisy diagnosis for patients with unexplained exudative pleuraleffusion who underwent a pleural biopsy via VATS: a prospective cohort study. International Journal of Infectious Diseases.2021 106:370-375. doi:10.1016/j.ijid.2021.04.011. 

15. Suting Chen#, Tianlu Teng#,Zhuman Zhang, Yuanyuan Shang, Hua Xiao, Guanglu Jiang, Fen Wang, Junnan Jia1,Lingling Dong, Liping Zhao, Naihui Chu*, HairongHuang*.Carbonyl cyanide3-chlorophenylhydrazone (CCCP) exhibits direct antibacterial activity againstMycobacterium abscessus. Infection and DrugResistance,2021;14:1199-1208. doi: 10.2147/IDR.S303113. eCollection2021

16. SunQ#, Wang S, Liao X, Jiang G, Huang H*, Li H*, Wang G*. Fidaxomicinhas high in vitro activity against Mycobacterium tuberculosis. J MedMicrobiol. 2021, 70(3). doi: 10.1099/jmm.0.001324.

17. Guirong Wang#,Guanglu Jiang#, Wei Jing, Zaojing Zong, XiaYu, Suting Chen, Weimin Li, HairongHuang*. Prevalence and molecular characterizations of seven additionaldrug resistance among multidrug-resistant tuberculosis in China: Asubsequent study of a national survey. JInfect. 2021, 82(3):371-377. doi:10.1016/j.jinf.2021.02.004.(IF:4.972)

18. Huang M#, Wang G#, SunQ, Jiang G, Li W, Ding Z, Jia H, Gao M, Huang H*, Li Q*. Diagnostic accuracy of Xpert MTB/RIF Ultra fortuberculous meningitis in a clinical practice setting of China.Diagn MicrobiolInfect Dis. 2021 Jan 6;100(1):115306. doi:10.1016/j.diagmicrobio.2020.115306.

19. Gong Z#,Wang G#,ZengJ,Stojkoska A,Huang H*,Xie J*. Differential DNA Methylomes of clinical MDR, XDR and XXDRMycobacterium tuberculosis isolates revealed by Using Single-Molecule Real-TimeSequencing. Journal of Drug Targeting.2021, 29(1):69-77. doi:10.1080/1061186X.2020.1797049.. 

20. Wen S, Zhang T.Yu X, Dong W,LanT,Fan J,Xue Y,Wang F,Dong L,Qin S*,Huang H*. The bone penetration of linezolid in osteoarticular tuberculosispatients of China. International Journal of Infectious Diseases.2021,103:364-369. doi: 10.1016/j.ijid.2020.11.203.

21. Chen S,Teng T,Wen S,Zhang T, Huang H*.The aceE involves in mycolicacid synthesis and biofilm formation in Mycobacterium smegmatis. BMCMicrobiology.2020

22. Zhou Z#, Li C#, Zhu R#,Wang D, Liu T,Jia J, Wang F,Zhao L,Dong L,Yu X*, Huang H*.Combination of percutaneouslung biopsy and Xpert MTB/RIF Ultra enhances differential diagnosis oftuberculosis: a prospective cohort study. Infectious Diseases and Therapy.2020,9(4):797-806.  doi: 10.1007/s40121-020-00327-0

23. Jing W, Zong Z,Tang H,Wang J,Zhang T, Wen S,Xue Y,Chu N*,Zhao W*, Huang H*.Population Pharmacokinetic Analysis of Isoniazid among Pulmonary TuberculosisPatients from China.Antimicrob Agents Chemother.,2020,64(3).pii:e01736-19.doi:10.1128/AAC.01736-19. 

24. Wang G, Wang S, Yang X, Sun Q, Jiang G, Huang M, Huo F, Ma Y, ChenX*, Huang H*. Accuracy of Xpert MTB/RIF Ultra for the diagnosis ofpleural tuberculosis in a multicentre cohort study. Chest, 2020 Feb;157(2):268-275. doi: 10.1016/j.chest.2019.07.027. 

25.Wang Y, Wang G, Wang Y, Xiao Jing,Sun L, Li J, Wen S, Zhang T,Ma Q, Huang H*, Shen A*.Development and clinical validationof multiple cross displacement amplification combined with nanoparticles-basedbiosensor for detection of Mycobacterium tuberculosis: preliminary results. Front.Microbiol. 2019，10:2135.doi: 10.3389/fmicb.2019.02135

26.  Sun Q, Wang S, Dong W, Jiang G, Huo F, Ma Y, Huang H*, Wang G*. Diagnostic value of XpertMTB/RIF Ultra for osteoarticular tuberculosis.J Infect. 2019 ; 79(2):153-158.

27.  Zhang T, Jiang G, Wen S, Huo F, Wang F, Huang H*,Pang Y*.Para-aminosalicylic acid increases the susceptibility to isoniazid in clinicalisolates  of Mycobacterium tuberculosis.InfectDrug Resist. 2019,12:825-829

28. YuX, Gao X, Li C, Luo J,Wen S ,Zhang Z, Ma Y,Dong L,Wang F, Huang H*. In Vitro Activity of bedaquiline and delamanid againstNon-tuberculous Mycobacteria isolated in Beijing, China. AAC,2019,63(8). pii: e00031-19.

29. Pang Y, Jing W, Lu J, ZongZ, Huo F, Dong L, Dai G, Li Y,  Huang H*, Chu N*.No in vitrosynergistic effect of bedaquiline combined with fluoroquinolones, linezolid,and clofazimine against extensively drug-resistant tuberculosis. Diagn Microbiol Infect Dis.2019 Aug;94(4):361-364

30. Liu R, Liang Q, Shang Y, MaY, Wang F, Dong L, Huang H*, Gao M*, Pang Y*. GeneXpert of stool versus gastric lavagefluid for the diagnosis of pulmonary tuberculosis in severely ill adults. Infection.2019 Aug;47(4):611-616.(IF:2.927) (IF：3.040)

31.    WangG#, Wang S#, Jiang G#, Yang X#,Huang M, Huo F,Ma Y, Dai G, Li W, ChenX*, Huang H*. Xpert MTB/RIF Ultra improved the diagnosis ofpaucibacillary tuberculosis: a prospective cohort study. J Infect,2019,78(4):311-316(IF:5.099) (IF：4.842)

32.   DaiG#, Chen S#, Dong L,Huo F, Shang Y,Huang H*. Determinationof the critical concentration of rifabutin for susceptibility testing using theproportion method with Löwenstein-Jensen medium against Mycobacteriumtuberculosis isolates. Lab Medicine，2019, 16;50(3):292-297

33.  Wen S, Jing W, Zhang T, ZongZ, Xue Y, Shang Y, Wang F, Huang H*, Chu N*, Pang Y*.Comparison of in vitro activity of thenitroimidazoles delamanid and pretomanid against multidrug-resistant andextensively drug-resistant tuberculosis.Eur J Clin Microbiol Infect Dis. 2019Jul;38(7):1293-1296. 

34.  Huang H#, Ding N#, Yang T#, Li C#, Jia X#, Wang G#, Zhong J, Zhang J, Jiang G, Wang S, Zong Z, Jing W, Zhao Y, XuS*, Chen F*. Cross-sectional whole-genome sequencing and epidemiological studyof multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis.2019,65:405-413

35. Sun L, Zhang L, Wang T, JiaoW, Li Q, Yin Q, Li J, Qi H, Xu F, Shen C, Xiao J, Liu S, Mokrousov I*, HuangH*, Shen A*. Mutations of Mycobacterium tuberculosis induced by anti-tuberculosis treatmentresult in metabolism changes and elevation of ethambutol resistance. Infect Genet Evol. 2019,72:151-158. 

36.  Yang T,Zhong J, Zhang J, Li C, Yu X, Xiao J,Jia X, Ding N, Ma G, Wang G,Yue L, Liang Q, Sheng Y, Sun Y, Huang H*, Chen F*. Pan-genomic study of Mycobacteriumtuberculosis reflecting the primary/secondary genes, generality/individuality,and the interconversion through copy number variations. Frontiers inMicrobiology, 2018, 9:1886. doi:10.3389/fmicb.2018.01886. 

37.  Zong Z, Huo F, Shi J, Jing W, Ma Y, Liang Q,Jiang G, Dai G, Huang H*, Pang Y.Relapse Versus Reinfection of Recurrent Tuberculosis Patients in aNational TuberculosisSpecialized Hospital in Beijing, China. FrontMicrobiol. 2018;9:1858. doi: 10.3389/fmicb.2018.01858. eCollection2018.

38.  Shi J, Lu J, Wen S, Zong Z, Huo F, Luo J, Liang Q, LiY, HuangH*, Pang Y. Invitro activity of PBTZ169 against multiple Mycobacterium species. AntimicrobAgents Chemother. 2018,62(11). pii: AAC.01314-18.

39.  Wang G, Dong W, Lan T, Fan J,Tang K, Li Y,Yan G,Jiang G, Ma Y,Shang Y, Qin S*, Huang H*.Diagnosticaccuracy evaluation of the conventional and molecular tests for SpinalTuberculosis in a cohort, head-to-head study. Emerging Microbes &Infections ，2018，7(1):109-117. doi: 10.1038/s41426-018-0114-1 

40. Luo J,Yu X, Jiang G,Fu Y, Huo F, Ma Y,Wang F, Shang Y, Liang Q, Xue Y, Huang H*. In Vitro Activity of Clofazimine against NontuberculousMycobacteria in China. Antimicrob. Agents Chemother.2018，62(7). pii:e00072-18. 

41. Zong Z, Jing W, Shi J, Wen S, Zhang T, Huo F,Shang Y, Liang Q, Huang H*,Pang Y. Comparison of in vitro activity and MIC distributions betweenthe novel oxazolidinone delpazolid and linezolid against multidrug-resistantand extensively drug-resistant Mycobacterium tuberculosis inChina. Antimicrob Agents Chemother. 2018，62(8). pii: AAC.00165-18. doi: 10.1128/AAC.00165-18. 

42.  Shi J, Dong W, Ma Y, Liang Q, Shang Y, WangF, Huang H*, Pang Y.GeneXpert MTB/RIF OutperformsMycobacterial Culture inDetecting Mycobacterium tuberculosis from Salivary Sputum.Biomed Res Int. 2018;1514381.

43. Wu X, Pang Y, Song Y, Dong W, Zhang T, Wen S, Huang H*, Gao M*. Implications of a school outbreak of multidrug-resistant tuberculosis in Northern China. Epidemiol Infect.2018;146(5):584-588.

44.  Huo F, Luo J, Shi J, Zong Z, WeiJing, Wenzhu Dong,Lingling Dong,Yifeng Ma, Qian Liang,Yuanyuan Shang,Huang H*,  Yu Pang. A 10-Year ComparativeAnalysis Shows that Increasing Prevalence of Rifampin-ResistantMycobacterium tuberculosis in China Is Associated with theTransmission of Strains Harboring Compensatory Mutations. .Agents Chemother.2018,62(4). pii: e02303-17. . 

45.  Wang Q, Pang Y, Jing W,Liu Y,Wang N, Yin H, ZhangQ,Ye Z, Zhu, M, Li M, Liu P, Wu T, Chen C,Wu W,Qin Z,Qiu C, DengQ, Xu T, Wang J, Guo R, Du Y, Wang J, Huang H, Chen X, and Chu N. Clofazimine for Treatment ofPulmonary Extensively Drug-Resistant Tuberculosis in China. Antimicrob. AgentsChemother. 2018,62(4). pii: e02149-17. .

46.  Wang G, Wang S, Jiang G, Fu Y,Shang S,Huang H*. Incrementalcost-effectiveness of the second Xpert MTB/RIFassay to detect Mycobacterium tuberculosis. Journalof Thoracic Disease. 2018，10(3):1689-1695 

47.  Tan J#,WuX#,ChenS,Gu M,Huang H*,Yue W*.Dominant epitopes derived from cell-wall protein LppZ for immunodiagnosticofpulmonary tuberculosis. BMC Immunology,2018,19(1):10

48. Xia Yu#, Xiling Zeng#,Wenhui Shi, YanjieHu, Wenjuan Nie, Naihui Chu*,  HuangH*.Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistantand Extensively Drug-Resistant Tuberculosis in Beijing, China. AAC 2018,62(3,pii: e01824-17 

49. Jing W#, Pang Y#, Zong Z, Wang J, Guo R, Huo F, Jiang G, Ma Y, Huang H*,Chu N*. Rifabutin Resistance Associated with Double Mutations in rpoB Genein Mycobacterium tuberculosis Isolates. Front Microbiol. 2017,;8:1768. doi: 10.3389/fmicb.2017.01768

50.  Pang Y#, Lu J, Huo F, Ma Y, Zhao L, Li Y, Liang Q, Chu N, Gao M, Huang H*.Prevalence and treatment outcome of extensively drug-resistant tuberculosis plusadditional drug resistance from the National Clinical Center for Tuberculosis in China: A five-yearreview. J Infect. 2017,75(5):433-440

51.  Pang Y#, Zong Z#, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, FuY, HuangH*. In vitro drug susceptibility of bedaquiline,delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin againstextensively drug –resistant tuberculosis from Beijing, China. Antimicrob AgentsChemother. 2017，61(10). 

52. Pang Y#, Shang Y#, Lu J, Liang Q, Dong L, Li Y, Zhao L, Jiang G, HuangH*. GeneXpert MTB/RIF assay in the diagnosis ofurinary tuberculosis from urine specimens. Sci Rep. 2017，21;7(1):6181

53. LiH#,Wang X,Wang B,Fu L,Liu G,Lu Y,Cao M,Huang H*, Javid B*.Latentlyand uninfected healthcare workers exposed to tuberculosis make protectiveantibodies against Mycobacterium tuberculosis.PNAS,2017, 114(19):5023-5028 

54.  Li QJ, Jiao WW, Yin QQ, Li YJ, Li JQ, Xu F, Sun L, Xiao J, Qi H,Wang T, Mokrousov I, Huang H*,Shen AD*.Positive epistasis of major low-cost drug resistance mutationsrpoB531-TTG and katG315-ACC depends on the phylogenetic background ofmycobacterium tuberculosis strains.Int J Antimicrob Agents. 2017

55.  ChenH#, He L#, HuangH#, Shi C, NiX, Dai G, Ma L, Li W. Mycobactrium tuberculosis Lineage Distribution in Xinjiang and Gansu Provinces, China.Sci Rep. 2017 Apr 21;7(1):1068. doi:10.1038/s41598-017-00720-9

56.  HuY, Wu X, Luo J, Fu Y, Zhao L, Ma Y, Li Y, Liang Q,Shang Y, Huang H*. Detection of pyrazinamide resistance of Mycobacteriumtuberculosis using nicotinamide as a surrogate. ClinicalMicrobiology and Infections.2017, 23(11):835-838

57.  Zeng X, Jing W, Zhang Y,Duan H, Lu Y, Dong Q, Huang H*, Chu N*. Performance of the MTBDRsl Line probe assay for rapiddetection of resistance to second-line anti-tuberculosis drugs and ethambutol inChina. Diagn Microbiol Infect Dis.2017，89(2)112-117.

58.  Jia X, Yang L, Dong M, Chen S, Lv L, Cao D,Fu J, Yang J, Zhang J,Zhang X, Shang Y, Wang G, Sheng Y, HuangH*, Chen F. The bioinformaticsanalysis of comparative genomics of Mycobacterium tuberculosis complex (MTBC)provides insight into dissimilarities between intraspecific groups differing inhost association, virulence and epitope diversity. Frontiersin Cellular and Infection Microbiology.2017,7:88.doi:10.3389/fcimb.2017.00088

59. Chen S,Han Y,Yu D,Huo F,Wang F,Li Y,DongL,Liu Z,Huang H*.Transdermal delivery of isoniazid andrifampin in guinea pigs by electro-phonophoresis. Drug Deliv. 2017,24:1, 467-470 

出版论著：

1.  《结核病研究进展报告.2020》，副主编， 北京，人民卫生出版社，2021年

2.  《结核病实验室检测与图解》主编，上海，上海科技出版社，2021年

3.  《非结核分枝杆菌病诊断与治疗》，副主编，北京，人民卫生出版社，2018年

获奖情况：

1.   “结核病诊断新技术的建立及推广应用”，北京医院科技奖（二等奖）（排名第一），2022年

2.   “非结核分枝杆菌病诊断技术的建立与应用推广”中国防痨协会科学技术奖（二等奖）（排名第一），2021年

3.   结核病诊疗关键技术的创新性研究；北京市科学技术奖（二等）（排名第四），2014年